Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Hidden hearing loss in a Charcot-Marie-Tooth type 1A mouse model
Luis R. Cassinotti, Lingchao Ji, M. Caroline Yuk, Aditi S. Desai, Nathan D. Cass, Zahara A. Amir, Gabriel Corfas
Luis R. Cassinotti, Lingchao Ji, M. Caroline Yuk, Aditi S. Desai, Nathan D. Cass, Zahara A. Amir, Gabriel Corfas
View: Text | PDF
Research Article Neuroscience Otology

Hidden hearing loss in a Charcot-Marie-Tooth type 1A mouse model

  • Text
  • PDF
Abstract

Hidden hearing loss (HHL), a recently described auditory neuropathy characterized by normal audiometric thresholds but reduced sound-evoked cochlear compound action potentials, has been proposed to contribute to hearing difficulty in noisy environments in people with normal hearing thresholds and has become a widespread complaint. While most studies on HHL pathogenesis have focused on inner hair cell (IHC) synaptopathy, we recently showed that transient auditory nerve (AN) demyelination also causes HHL in mice. To test the effect of myelinopathy on hearing in a clinically relevant model, we studied a mouse model of Charcot-Marie-Tooth type 1A (CMT1A), the most prevalent hereditary peripheral neuropathy in humans. CMT1A mice exhibited the functional hallmarks of HHL together with disorganization of AN heminodes near the IHCs with minor loss of AN fibers. These results support the hypothesis that mild disruptions of AN myelination can cause HHL and that heminodal defects contribute to the alterations in the sound-evoked cochlear compound action potentials seen in this mouse model. Furthermore, these findings suggest that patients with CMT1A or other mild peripheral neuropathies are likely to suffer from HHL. Furthermore, these results suggest that studies of hearing in patients with CMT1A might help develop robust clinical tests for HHL, which are currently lacking.

Authors

Luis R. Cassinotti, Lingchao Ji, M. Caroline Yuk, Aditi S. Desai, Nathan D. Cass, Zahara A. Amir, Gabriel Corfas

×

Figure 2

Distinct effects of CMT1A and CMT1E on signaling along the ascending auditory pathway.

Options: View larger image (or click on image) Download as PowerPoint
Distinct effects of CMT1A and CMT1E on signaling along the ascending aud...
(A) Mean ABR waveforms recorded at 1, 2, 3, and 4 months of age show a progressive delay and reduction of the first ABR peak in both CMT1 mouse models. CMT1E phenotype is more severe than in CMT1A mice, affecting the later ABR peaks along the ascending auditory pathway. ABRs shown here are group means in response to 16 kHz tone pips at 80 dB SPL. Data are shown as mean ± SEM. (B) Quantification of ABR amplitudes in peak II, III, IV, and V at 4 months of age shows that CMT1E mice have decreased signaling along the ascending auditory pathway while, in CMT1A mice, this signaling is normal compared with WT mice. ABR peak II–V amplitudes were evaluated at 16 kHz cochlear frequency and at suprathreshold levels (80 dB SPL). WT, n = 15 mice; CMT1A, n = 10 mice; CMT1E, n = 12 mice. One-way ANOVA followed by Tukey’s multiple-comparison test was used to evaluate statistical differences among the experimental groups. ***P < 0.001; ****P < 0.0001. Data are shown as mean ± SEM.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts